Literature DB >> 34854146

Sex-specific developmental trajectories of eczema from infancy to age 26 years: A birth cohort study.

Ali H Ziyab1, Nandini Mukherjee2, Hongmei Zhang2, Syed Hasan Arshad3,4, Wilfried Karmaus2.   

Abstract

BACKGROUND: Eczema is a common inflammatory skin disease with varying developmental trajectories/patterns that are influenced by different risk factors. The aim of this study was to investigate eczema development from infancy to early adulthood by identifying distinct developmental trajectories that describe disease patterns over time and evaluate the role of prenatal and early-life risk factors.
METHODS: The Isle of Wight Birth Cohort (n = 1456) was prospectively assessed at birth, 1, 2, 4, 10, 18 and 26 years. In all assessments, eczema was defined as chronic or chronically relapsing itchy dermatitis lasting >6 weeks with characteristic morphology and distribution in the past 12 months. Developmental trajectories of eczema between 1 or 2 and 26 years were identified separately for males and females by applying semiparametric mixture models. Associations were assessed by applying a modified Poisson regression to estimate adjusted risk ratios (aRR) and 95% confidence intervals (CI).
RESULTS: In both males and females, the following eczema developmental trajectories were identified: unaffected/transient (males: 77.7% vs. females: 73.0%), mid-onset late-resolving (males: 7.8% vs. females: 4.4%), late-onset (males: 5.2% vs. females: 9.5%) and early-onset persistent (males: 9.3% vs. females: 5.4%). In females, an additional trajectory was identified as follows: early-onset early-resolving (7.7%). Among males, filaggrin gene (FLG) variants (aRR = 2.45, 95% CI: 1.34-4.46) and paternal eczema (2.66, 1.39-5.08) were associated with the early-onset persistent trajectory. Among females, maternal eczema (2.84, 1.42-5.70) and high birthweight (2.25, 1.08-4.69) were associated with the early-onset persistent trajectory.
CONCLUSIONS: Four and five trajectories represented eczema development among males and females, respectively, with different predisposing risk factors. Our results indicate that males and females may experience a different course of eczema.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  atopic dermatitis; basic mechanisms; dermatology; epidemiology; natural history; trajectories

Mesh:

Year:  2021        PMID: 34854146      PMCID: PMC8866217          DOI: 10.1111/cea.14068

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  51 in total

1.  A long-term follow-up of allergic diseases in Iceland.

Authors:  Anna Freyja Finnbogadóttir; Björn Árdal; Herbert Eiríksson; Birgir Hrafnkelsson; Helgi Valdimarsson; Björn Rúnar Lúðvíksson; Ásgeir Haraldsson
Journal:  Pediatr Allergy Immunol       Date:  2012-02-02       Impact factor: 6.377

Review 2.  Clinical practice. Atopic dermatitis.

Authors:  Hywel C Williams
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

3.  Trends in eczema in the first 18 years of life: results from the Isle of Wight 1989 birth cohort study.

Authors:  A H Ziyab; A Raza; W Karmaus; N Tongue; H Zhang; S Matthews; S H Arshad; G Roberts
Journal:  Clin Exp Allergy       Date:  2010-12       Impact factor: 5.018

4.  The natural course of sensitization and allergic diseases from childhood to adulthood.

Authors:  Susanne P Nissen; Henrik F Kjaer; Arne Høst; Jan Nielsen; Susanne Halken
Journal:  Pediatr Allergy Immunol       Date:  2013-07-31       Impact factor: 6.377

5.  The natural history of eczema from birth to adult life: a cohort study.

Authors:  M L Burr; F D J Dunstan; S Hand; J R Ingram; K P Jones
Journal:  Br J Dermatol       Date:  2013-06       Impact factor: 9.302

6.  Four childhood atopic dermatitis subtypes identified from trajectory and severity of disease and internally validated in a large UK birth cohort.

Authors:  A R Mulick; K E Mansfield; R J Silverwood; A Budu-Aggrey; A Roberts; A Custovic; N Pearce; A D Irvine; L Smeeth; K Abuabara; S M Langan
Journal:  Br J Dermatol       Date:  2021-05-09       Impact factor: 11.113

7.  Epidemiologic methods of assessing asthma and wheezing episodes in longitudinal studies: measures of change and stability.

Authors:  Nelís Soto-Ramírez; Ali H Ziyab; Wilfried Karmaus; Hongmei Zhang; Ramesh J Kurukulaaratchy; Susan Ewart; Syed Hasan Arshad
Journal:  J Epidemiol       Date:  2013-08-31       Impact factor: 3.211

8.  Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts.

Authors:  Lavinia Paternoster; Olga E M Savenije; Jon Heron; David M Evans; Judith M Vonk; Bert Brunekreef; Alet H Wijga; A John Henderson; Gerard H Koppelman; Sara J Brown
Journal:  J Allergy Clin Immunol       Date:  2017-11-10       Impact factor: 10.793

Review 9.  Disease trajectories in childhood atopic dermatitis: an update and practitioner's guide.

Authors:  A D Irvine; P Mina-Osorio
Journal:  Br J Dermatol       Date:  2019-05-15       Impact factor: 9.302

10.  Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis.

Authors:  Colin N A Palmer; Alan D Irvine; Ana Terron-Kwiatkowski; Yiwei Zhao; Haihui Liao; Simon P Lee; David R Goudie; Aileen Sandilands; Linda E Campbell; Frances J D Smith; Gráinne M O'Regan; Rosemarie M Watson; Jo E Cecil; Sherri J Bale; John G Compton; John J DiGiovanna; Philip Fleckman; Sue Lewis-Jones; Gehan Arseculeratne; Ann Sergeant; Colin S Munro; Brahim El Houate; Ken McElreavey; Liselotte B Halkjaer; Hans Bisgaard; Somnath Mukhopadhyay; W H Irwin McLean
Journal:  Nat Genet       Date:  2006-03-19       Impact factor: 38.330

View more
  1 in total

Review 1.  Establishing subclasses of childhood eczema, their risk factors and prognosis.

Authors:  Diego J Lopez; Caroline J Lodge; Dinh S Bui; Nilakshi T Waidyatillake; Michael J Abramson; Jennifer L Perret; John C Su; Bircan Erbas; Cecilie Svanes; Shyamali C Dharmage; Adrian J Lowe
Journal:  Clin Exp Allergy       Date:  2022-04-04       Impact factor: 5.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.